AnBaiNuo (etanercept biosimilar) / Zhejiang Hisun 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   12 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AnBaiNuo (etanercept biosimilar) / Zhejiang Hisun
ChiCTR2000032534: Pharmacoeconomic evaluation of Anbainuo in the treatment of moderate to severe rheumatoid arthritis - a single center, control study

Completed
4
90
 
Anbainuo plus methotrexate ;Methotrexate, salazopyridine, leflumide, hydroxychloroquine
The Affiliated ZhuZhou Hospital Of XiangYa School Of Medicine CSU.; The Affiliated ZhuZhou Hospital Of XiangYa School Of Medicine CSU., self-paying
Rheumatoid arthritis
 
 
AnBaiNuo1: A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheu

Completed
3
396
China
AnBaiNuo (etanercept biosimilar)
Shanghai JiaoTong
Rheumatoid arthritis
 
 
ChiCTR1900025749: Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study

Not yet recruiting
N/A
350
 
conventional synthetic Disease modifying anti-rheumatic drugs(csDMARDs) ;Etanercept (Anbainuo 50mg per week, for 4 weeks) ;Etanercept (Anbainuo 50mg per week, for 2 weeks) ;Etanercept (Anbainuo 50mg per week, for 12 weeks) ;Etanercept (Anbainuo 50mg per 10 days, for 12 weeks) ;Etanercept (Anbainuo 25mg per week, for 12 weeks) ;Etanercept (Anbainuo 25mg per 2 weeks, for 12 weeks)
Nanfang Hospital of Southern Medical University; NanFang Hospital of Southern Medical University, Latitudinal Project
Ankylosing Spondylitis
 
 

Download Options